NCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
Clinical Trials
20 trialsNCT00135200 2025-04-30
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT00329030 2021-11-01
BMTCTN0401
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00992992 2019-12-04
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT00770224 2019-08-28
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00476047 2017-10-12
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01536561 2017-08-31
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 1 Completed
NCT00577629 2017-05-30
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Duke University
Phase 2 Completed
NCT00490490 2017-03-29
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
Stanford University
Phase 2 Terminated
NCT01389076 2017-01-30
Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00950755 2017-01-18
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
GlaxoSmithKline
Phase 2 Completed
NCT00996996 2017-01-11
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT00268983 2017-01-09
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
GlaxoSmithKline
Phase 3 Completed
NCT00938041 2017-01-09
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
GlaxoSmithKline
Phase 2 Completed
NCT00989664 2016-12-13
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT01224821 2016-12-12
RIT-II-001
GlaxoSmithKline
Phase 2 Completed
NCT00996593 2016-11-23
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
GlaxoSmithKline
Phase 2 Completed
NCT00107380 2016-03-07
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00475332 2012-02-15
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
University of Florida
Phase 2 Terminated